Format

Send to

Choose Destination
Lancet Oncol. 2004 Mar;5(3):174-81.

Oestrogen receptor beta: what it means for patients with breast cancer.

Author information

1
Molecular Medicine Unit, University of Leeds, Leeds, UK. v.speors@leeds.ac.uk

Erratum in

  • Lancet Oncol. 2004 Apr;5(4):208.

Abstract

Oestrogen receptor (ER) alpha is a well established prognostic marker in breast cancer, and all patients who are ER alpha positive receive tamoxifen as adjuvant endocrine therapy. Although ER alpha predicts a favourable disease outcome, the usefulness of ER beta as a clinical prognostic marker remains to be defined. Here, we outline the history of both ERs and discuss the implications ER beta has to patients with breast cancer.

PMID:
15003201
DOI:
10.1016/S1470-2045(04)01413-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center